Parametric Portfolio Associates’s Castle Biosciences CSTL Stock Holding History

Parametric Portfolio Associates’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.56M	Buy	57,092 +14,120	+33%	+$584K	﹤0.01%	2290
2021 Q4	$1.84M	Buy	42,972 +9,862	+30%	+$515K	﹤0.01%	2483
2021 Q3	$2.2M	Sell	33,110 -2,286	-6%	-$161K	﹤0.01%	2395
2021 Q2	$2.6M	Buy	35,396 +1,716	+5%	+$113K	﹤0.01%	2289
2021 Q1	$2.31M	Buy	33,680 +9,080	+37%	+$682K	﹤0.01%	2688
2020 Q4	$1.65M	Sell	24,600 -19,161	-44%	-$1.04M	﹤0.01%	2787
2020 Q3	$2.25M	Buy	43,761 +6,310	+17%	+$281K	﹤0.01%	2438
2020 Q2	$1.41M	Sell	37,451 -14,184	-27%	-$485K	﹤0.01%	2718
2020 Q1	$1.54M	Buy	51,635 +40,529	+365%	+$1.22M	﹤0.01%	2543
2019 Q4	$382K	Buy	11,106 +350	+3%	+$8.56K	﹤0.01%	3475
2019 Q3	$195K	Buy	+10,756	New	+$238K	﹤0.01%	3715

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Parametric Portfolio Associates's CSTL Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Castle Biosciences (CSTL) stake by 33% in Q1 2022, buying an estimated $584K and bringing the position to 57,092 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Parametric Portfolio Associates first reported a position in CSTL in Q3 2019 and has held it in 11 quarters since. The position peaked at $2.6M in Q2 2021. 160 funds tracked by Wall St. Rank hold CSTL as of Q1 2022.

Parametric Portfolio Associates held 57,092 shares of Castle Biosciences worth $2.56M as of Q1 2022.
Parametric Portfolio Associates bought 14,120 Castle Biosciences shares in Q1 2022, an estimated $584K.
Castle Biosciences made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2290 holding.
Parametric Portfolio Associates first reported a position in Castle Biosciences in Q3 2019 and has held it in 11 quarters since.
Parametric Portfolio Associates's Castle Biosciences position peaked at $2.6M in Q2 2021.
160 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.